SCHEMBL2279724

SCHEMBL2279724

CC(=O)OCCNC(=O)OC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.53
CA12 O43570 7/20 0.51
CA1 P00915 7/20 0.51
CA2 P00918 7/20 0.51
CA9 Q16790 7/20 0.51
IDO1 P14902 2/20 0.51
MEN1 O00255 1/20 0.50
GAA P10253 1/20 0.50
KMT2A Q03164 1/20 0.50
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
EPHX1 P07099 1/20 0.44
MALT1 Q9UDY8 1/20 0.41
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 1/20 0.39
GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4644425 0.92 TDP1 (0.46) TDP1CA12CA1CA2CA9
SCHEMBL28500736 0.90 TDP1 (0.47) TDP1CA12CA1CA2CA9
SCHEMBL1063374 0.89 CA12 (0.60) TDP1CA12CA1CA2CA9
Hydrochloric Acid SCHEMBL27999755 0.88 TDP1 (0.46) TDP1CA12CA1CA2CA9
SCHEMBL1063562 0.87 CA12 (0.68) TDP1CA12CA1CA2CA9
SCHEMBL27841306 0.87 IDO1 (0.54) TDP1CA12CA1CA2CA9
SCHEMBL30206955 0.86 TDP1 (0.55) TDP1CA12CA1CA2CA9
SCHEMBL28903507 0.85 TDP1 (0.53) TDP1CA12CA1CA2CA9
SCHEMBL11888006 0.85 TDP1 (0.53) TDP1CA12CA1CA2CA9
SCHEMBL8274545 0.85 IDO1 (0.55) TDP1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839657-B2 Ionizable lipids and compositions for nucleic acid delivery WESTGENE BIOPHARMA CO., LTD (CN) 2023-12-12 US disclosed
WO-2018091467-A2 A SIMULTANEOUSLY ANTIMICROBIAL AND PROTEIN-REPELLENT POLYZWITTERION ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2018-05-24 WO disclosed
US-7989634-B2 Melanocortin receptor agonists LG LIFE SCIENCES LTD. (KR) 2011-08-02 US disclosed
EP-1685102-A4 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD (KR) 2008-08-20 EP disclosed
US-20070129346-A1 Melanocortin receptor agonists LG LIFE SCIENCES LTD. (KR) 2007-06-07 US disclosed
EP-1685102-A1 MELANOCORTIN RECEPTOR AGONISTS LG Life Sciences Ltd. (KR) 2006-08-02 EP disclosed
WO-2005047251-A1 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD. (KR) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129346-A1 Melanocortin receptor agonists MC1R, MC3R, MC5R TDP1 4686/4885CA12 2064/4885CA1 1598/4885
US-11839657-B2 Ionizable lipids and compositions for nucleic acid delivery POLRMT, POLN, NPC1L1 TDP1 692/4885CA12 1350/4885CA1 2466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.